Latest information on COVID-19
Support teaching, research, and patient care.
Zinaida Good, Ph.D. is a postdoctoral fellow working at the intersection of systems biology and cancer immunotherapy at Stanford University. Good’s research with Crystal L. Mackall and Sylvia K. Plevritis is focused on investigating why engineered cellular immunotherapies succeed or fail in patients. Leveraging multimodal single-cell analysis, tumor microenvironment imaging, and data integration, she aims to identify features of optimal engineered T cells from patient data. Good earned her doctorate in computational and systems immunology from Stanford University in 2018, where she trained with Garry P. Nolan and Sean C. Bendall. Her background is in immunology — with bachelor’s and master’s degrees from the University of British Columbia — and oncology, having worked for two years in discovery oncology at Genentech. Good is an inventor on two patent applications, has co-authored 12 papers, published four first-author manuscripts (Good and Sarno et al. Nature Medicine, 2018; Good et al. Nature Biotechnology, 2019; Good et al. Trends in Immunology, 2019; Good and Spiegel et al. Nature Medicine, 2022), and has been named a Parker Institute for Cancer Immunotherapy Scholar, a Stanford Cancer Institute Fellow, and an Arthur and Sandra Irving Cancer Immunology Fellow. Good’s long-term goal is to understand and enhance engineered cellular immunotherapies for patients with cancer.